Special Issue "Marine Compounds as Protein Kinase Inhibitors"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 January 2013)

Special Issue Editor

Guest Editor
Prof. Dr. Christian Peifer
Department of Pharmaceutical Chemistry, Christian Albrechts University, Gutenbergstraße 76, 24118 Kiel, Germany
Website: http://www.uni-kiel.de/pharmazie/chem/Prof_Peifer/index.htm
E-Mail: cpeifer@pharmazie.uni-kiel.de
Phone: +49 431 880 1137
Fax: +49 431 880 1352
Interests: design; synthesis and biological evaluation of protein kinase inhibitors

Special Issue Information

Dear Colleagues,

Biologically active marine derived compounds have been shown to represent an interesting source of novel compounds that are protein kinase inhibitors (PKI). Protein kinases (PK) are validated targets for drug discovery, particularly in cancer. Thus far, a number of potent natural product PKI’s and PK modulators have been isolated including secondary metabolites from marine organisms and these have been useful as pharmacological tools and lead structures to develop novel PKI’s.

Despite their original biological functions, marine compounds often have non-optimal properties when evaluated in vivo such as inappropriate pharmacokinetic properties, or structural complexity that makes them difficult for scale-up synthesis. Therefore, significant medicinal chemistry is often required in order to optimize these compounds for drug discovery purposes. Despite these challenges, a large pool of marine organisms is available to search for novel compounds that could act as novel PKI’s.

Staurosporine, a nonspecific and thus toxic PKI inhibits many of the 518 human PK with high potency and this represents an early and well-known natural product derived PKI. The use of Staurosporine has led to a wealth of ligand-PK structures, providing significant structure-based design opportunities towards more specific PKI’s. The marine-sponge derived Hymenialdisines were discovered as potent inhibitors of PK involved in inflammation, thus blocking interleukin-2/TNF-alpha cytokine production. Subsequently, Hymenialdisine-derived indoloazepine derivatives were optimized leading to selective CHK1 and CHK2 inhibitors. The marine sponge-derived bis-indole alkaloide Fascaplysin, was reported to be a selective CDK4/cyclin D1 ligand. Furthermore, the macrolid lactone Bryostatin-1 produced by Bryozoa, marine invertebrate animals was characterized as a potent modulator of Protein Kinase C. These examples illustrate the importance of marine-derived PKI’s, and no-doubt more novel compounds will be discovered from the oceans in the future.

This Special Issue of Marine Drugs will focus on the exciting area of marine-derived compounds which may allow for novel approaches in PKI drug discovery.


Prof. Dr. Christian Peifer
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).

Keywords

  • protein kinase inhibitors (PKI)
  • small molecule PKI (smPKI)
  • marine sponge metabolites
  • potency and selectivity
  • Staurosporine bisindole alkaloids
  • bryostatin-1
  • hymenialdisine
  • fascaplysin
  • anti-cancer activity
  • antibiotic activity

Published Papers (3 papers)

Mar. Drugs 2013, 11(9), 3209-3223; doi:10.3390/md11093209
Received: 7 June 2013; in revised form: 1 August 2013 / Accepted: 8 August 2013 / Published: 26 August 2013
Show/Hide Abstract | Download PDF Full-text (807 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(3), 944-959; doi:10.3390/md11030944
Received: 28 December 2012; in revised form: 21 January 2013 / Accepted: 22 February 2013 / Published: 20 March 2013
Show/Hide Abstract | Download PDF Full-text (903 KB) | View HTML Full-text |  Supplementary Files

Mar. Drugs 2013, 11(3), 903-933; doi:10.3390/md11030903
Received: 4 February 2013; in revised form: 25 February 2013 / Accepted: 1 March 2013 / Published: 15 March 2013
Show/Hide Abstract | Download PDF Full-text (1747 KB) | View HTML Full-text | Download XML Full-text

Last update: 10 October 2012

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert